Have a personal or library account? Click to login
Cytotoxicity-related effects of imidazolium and chlorinated bispyridinium oximes in SH-SY5Y cells Cover

Cytotoxicity-related effects of imidazolium and chlorinated bispyridinium oximes in SH-SY5Y cells

Open Access
|Dec 2022

Figures & Tables

Figure 1

Structures of oximes tested in this study
Structures of oximes tested in this study

Figure 2

ATP in SH-SY5Y cells after 4 h exposure to selected oximes expressed as the percentage of control (untreated cells). Oxime concentrations: K867 (400 μM), K870 (15 μM), VII (250 μM) and X (200 μM). #p≤0.01; *p≤0.0001
ATP in SH-SY5Y cells after 4 h exposure to selected oximes expressed as the percentage of control (untreated cells). Oxime concentrations: K867 (400 μM), K870 (15 μM), VII (250 μM) and X (200 μM). #p≤0.01; *p≤0.0001

Figure 3

Time-dependent effects of the selected oximes K867 (400 μmol/L), K870 (15 μmol/L), VII (250 μmol/L), and X (200 μmol/L) on intracellular signalling in serum-starved SH-SY5Y cells over 5–60 min. Position towards bends and molecular weight markers in kDa are indicated on the right side of the blots and Ponceau S. Results are presented as means ± SD (n=9) &p≤0.05; #p≤0.01; $p≤0.001; *p≤0.0001. B– baseline; pERK1/2 – phospho-ERK1/2 (Thr202/Tyr204); pNFkB – phospho-NFκbeta p65 (Ser536); p-p38MAPK – phospho-p38MAPK (Thr180/Tyr182); p-STAT3 – phospho-STAT3 (Tyr705); p-ACC – phospho-ACC (Ser79); p-AMPKα – phospho-AMPKalpha (Thr172); t– time
Time-dependent effects of the selected oximes K867 (400 μmol/L), K870 (15 μmol/L), VII (250 μmol/L), and X (200 μmol/L) on intracellular signalling in serum-starved SH-SY5Y cells over 5–60 min. Position towards bends and molecular weight markers in kDa are indicated on the right side of the blots and Ponceau S. Results are presented as means ± SD (n=9) &p≤0.05; #p≤0.01; $p≤0.001; *p≤0.0001. B– baseline; pERK1/2 – phospho-ERK1/2 (Thr202/Tyr204); pNFkB – phospho-NFκbeta p65 (Ser536); p-p38MAPK – phospho-p38MAPK (Thr180/Tyr182); p-STAT3 – phospho-STAT3 (Tyr705); p-ACC – phospho-ACC (Ser79); p-AMPKα – phospho-AMPKalpha (Thr172); t– time

Figure 4

Target class frequencies of oximes K867, K870, VII, and X predicted by the SwissTargetPrediction engine. The dashed frame highlights the family of G-protein-coupled receptors as the most probable target of interaction
Target class frequencies of oximes K867, K870, VII, and X predicted by the SwissTargetPrediction engine. The dashed frame highlights the family of G-protein-coupled receptors as the most probable target of interaction

Figure 5

iCa2+ levels in SH-SY5Y cells before and after the addition of ACh (5 μmol/L) in the presence of oximes K867 (400 μmol/L), K870 (25 μmol/L), VII (250 μmol/L), and X (200 μmol/L) compared to control (not treated with the oximes)
iCa2+ levels in SH-SY5Y cells before and after the addition of ACh (5 μmol/L) in the presence of oximes K867 (400 μmol/L), K870 (25 μmol/L), VII (250 μmol/L), and X (200 μmol/L) compared to control (not treated with the oximes)

Primary antibodies (Cell Signaling Technology Inc, USA) used for Western blotting

AntibodyCat. No.HostTypeDilution
Anti p-ERK (Thr202/Tyr204)#4370RabbitMonoclonal1:2000
Anti pNFκB p65 (Ser536)#3033RabbitMonoclonal1:2000
Anti p-p38 MAPK (Thr180/Tyr182)#4511RabbitMonoclonal1:1000
Anti p-STAT3 (Tyr705)#9145RabbitMonoclonal1:1000
Anti p-ACC (Ser79)#3661RabbitPolyclonal1:1000
Anti p-AMPKα (Thr172)#2535RabbitMonoclonal1:1000
DOI: https://doi.org/10.2478/aiht-2022-73-3688 | Journal eISSN: 1848-6312 | Journal ISSN: 0004-1254
Language: English, Croatian, Slovenian
Page range: 277 - 284
Submitted on: Oct 1, 2022
Accepted on: Dec 1, 2022
Published on: Dec 30, 2022
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 Antonio Zandona, Tamara Zorbaz, Katarina Miš, Sergej Pirkmajer, Maja Katalinić, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.